Business Wire

CASTLE ROCK, Colo.--(BUSINESS WIRE)-- Riot Platforms, Inc. (“Riot”) issues this press release pursuant to Part 3 of Canadian National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and Part 5 of Canadian National Instrument 62-104 – Take-Over Bids and Issuer Bids in respect of Bitfarms Ltd. (the “Company”).

Riot announces that on June 13, 2024 it acquired ownership of 1,432,063 common shares (the “Purchased... (continue reading...)

HOUSTON--(BUSINESS WIRE)-- Crescent Energy Company (NYSE: CRGY) (“we” or “our”) announced today that its indirect subsidiary Crescent Energy Finance LLC (the “Issuer”) has priced its previously announced offer pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”), to eligible purchasers of $750 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”). The Notes mature on January 15, 2033... (continue reading...)

42 MW Solar Paired with 42 MW Battery Storage in ‘Ewa is Now Powering 10,000 Homes with Clean, Renewable Energy

FRAMINGHAM, Mass. & HONOLULU, HI--(BUSINESS WIRE)-- Ameresco, Inc., (NYSE: AMRC), a leading cleantech integrator specializing in energy efficiency and renewable energy, today announced the commercial operations and dedication ceremony for Kūpono Solar. The solar and battery storage facility, located at Joint Base Pearl Harbor-Hickam West Loch Annex, is... (continue reading...)

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company”) announces that at its annual general meeting of shareholders held on June 12, 2024 (the “Meeting”), all directors listed in the Information Circular dated May 9, 2024 were elected. The detailed results are as follows:

Nominee Director

Votes For

% Votes For

Votes Withheld

% Votes Withheld

Sofia... (continue reading...)

• CT-P47 was highly similar in terms of efficacy and safety to the reference product RoActemra® (tocilizumab) for the treatment of rheumatoid arthritis (RA) up to week 321
• High usability of the CT-P47 autoinjector (AI) was observed in RA patients, offering greater flexibility and an alternative treatment option

INCHEON, South Korea--(BUSINESS WIRE)-- Celltrion today presented positive Phase III data for CT-P47, a biosimilar candidate referencing RoActemra® in... (continue reading...)